EMEA-002363-PIP01-18

Key facts

Active substance
3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
Therapeutic area
  • Cardiovascular diseases
  • Neurology
Decision number
P/0330/2018
PIP number
EMEA-002363-PIP01-18
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of transthyretin amyloidosis (ATTR amyloidosis)
Route(s) of administration
Oral use
Contact for public enquiries
Eidos Therapeutics, Inc.

Tel.  +1415 887 1471
E-mail: info@eidostx.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating